Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53


Cell death and regeneration in Dresden-the 27th meeting of the European Cell Death Organization.

Linkermann A, Kulms D.

Cell Death Dis. 2019 Dec 4;10(12):910. doi: 10.1038/s41419-019-2153-5. No abstract available.


Identifying and targeting cancer-specific metabolism with network-based drug target prediction.

Pacheco MP, Bintener T, Ternes D, Kulms D, Haan S, Letellier E, Sauter T.

EBioMedicine. 2019 May;43:98-106. doi: 10.1016/j.ebiom.2019.04.046. Epub 2019 May 22.


Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.

Margue C, Philippidou D, Kozar I, Cesi G, Felten P, Kulms D, Letellier E, Haan C, Kreis S.

J Exp Clin Cancer Res. 2019 Feb 6;38(1):56. doi: 10.1186/s13046-019-1038-x.


Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma.

Del Mistro G, Lucarelli P, Müller I, De Landtsheer S, Zinoveva A, Hutt M, Siegemund M, Kontermann RE, Beissert S, Sauter T, Kulms D.

NPJ Syst Biol Appl. 2018 Nov 5;4:39. doi: 10.1038/s41540-018-0075-y. eCollection 2018.


Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma.

Rožanc J, Sakellaropoulos T, Antoranz A, Guttà C, Podder B, Vetma V, Rufo N, Agostinis P, Pliaka V, Sauter T, Kulms D, Rehm M, Alexopoulos LG.

Cell Death Differ. 2019 Aug;26(8):1365-1378. doi: 10.1038/s41418-018-0210-8. Epub 2018 Oct 15.


A 3D Organotypic Melanoma Spheroid Skin Model.

Müller I, Kulms D.

J Vis Exp. 2018 May 18;(135). doi: 10.3791/57500.


IgG-single-chain TRAIL fusion proteins for tumour therapy.

Siegemund M, Schneider F, Hutt M, Seifert O, Müller I, Kulms D, Pfizenmaier K, Kontermann RE.

Sci Rep. 2018 May 17;8(1):7808. doi: 10.1038/s41598-018-24450-8.


Superior Properties of Fc-comprising scTRAIL Fusion Proteins.

Hutt M, Marquardt L, Seifert O, Siegemund M, Müller I, Kulms D, Pfizenmaier K, Kontermann RE.

Mol Cancer Ther. 2017 Dec;16(12):2792-2802. doi: 10.1158/1535-7163.MCT-17-0551. Epub 2017 Sep 13.


BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.

Niessner H, Sinnberg T, Kosnopfel C, Smalley KSM, Beck D, Praetorius C, Mai M, Beissert S, Kulms D, Schaller M, Garbe C, Flaherty KT, Westphal D, Wanke I, Meier F.

Clin Cancer Res. 2017 Oct 15;23(20):6203-6214. doi: 10.1158/1078-0432.CCR-17-0098. Epub 2017 Jul 19.


PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.

Niessner H, Schmitz J, Tabatabai G, Schmid AM, Calaminus C, Sinnberg T, Weide B, Eigentler TK, Garbe C, Schittek B, Quintanilla-Fend L, Bender B, Mai M, Praetorius C, Beissert S, Schackert G, Muders MH, Meinhardt M, Baretton GB, Dummer R, Flaherty K, Pichler BJ, Kulms D, Westphal D, Meier F.

Clin Cancer Res. 2016 Dec 1;22(23):5818-5828. Epub 2016 Jun 15. Erratum in: Clin Cancer Res. 2017 Mar 1;23 (5):1361.


The TAT-RasGAP317-326 anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner.

Heulot M, Chevalier N, Puyal J, Margue C, Michel S, Kreis S, Kulms D, Barras D, Nahimana A, Widmann C.

Oncotarget. 2016 Sep 27;7(39):64342-64359. doi: 10.18632/oncotarget.11841.


Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines.

Henry CM, Sullivan GP, Clancy DM, Afonina IS, Kulms D, Martin SJ.

Cell Rep. 2016 Feb 2;14(4):708-722. doi: 10.1016/j.celrep.2015.12.072. Epub 2016 Jan 14.


Anti-apoptotic NF-κB and "gain of function" mutp53 in concert act pro-apoptotic in response to UVB+IL-1 via enhanced TNF production.

Müller I, Beissert S, Kulms D.

J Invest Dermatol. 2015 Mar;135(3):851-860. doi: 10.1038/jid.2014.481. Epub 2014 Nov 7.


Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.

Bullenkamp J, Raulf N, Ayaz B, Walczak H, Kulms D, Odell E, Thavaraj S, Tavassoli M.

Cell Death Dis. 2014 Oct 23;5:e1489. doi: 10.1038/cddis.2014.455.


Differential response of head and neck cancer cell lines to TRAIL or Smac mimetics is associated with the cellular levels and activity of caspase-8 and caspase-10.

Raulf N, El-Attar R, Kulms D, Lecis D, Delia D, Walczak H, Papenfuss K, Odell E, Tavassoli M.

Br J Cancer. 2014 Nov 11;111(10):1955-64. doi: 10.1038/bjc.2014.521. Epub 2014 Oct 14.


Identification of new IκBα complexes by an iterative experimental and mathematical modeling approach.

Konrath F, Witt J, Sauter T, Kulms D.

PLoS Comput Biol. 2014 Mar 27;10(3):e1003528. doi: 10.1371/journal.pcbi.1003528. eCollection 2014 Mar.


Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.

Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J, Tabatabai G, Flaherty K, Sinnberg T, Beck D, Leiter U, Mauch C, Roesch A, Weide B, Eigentler T, Schadendorf D, Garbe C, Kulms D, Quintanilla-Martinez L, Meier F.

Cancer Med. 2013 Feb;2(1):76-85. doi: 10.1002/cam4.50. Epub 2013 Feb 3.


Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing.

Vörsmann H, Groeber F, Walles H, Busch S, Beissert S, Walczak H, Kulms D.

Cell Death Dis. 2013 Jul 11;4:e719. doi: 10.1038/cddis.2013.249.


Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.

Beck D, Niessner H, Smalley KS, Flaherty K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Drießen S, Stork B, Wesselborg S, Schaller M, Biedermann T, Bauer J, Lasithiotakis K, Weide B, Eberle J, Schittek B, Schadendorf D, Garbe C, Kulms D, Meier F.

Sci Signal. 2013 Jan 29;6(260):ra7. doi: 10.1126/scisignal.2003057.


Analysing the role of UVB-induced translational inhibition and PP2Ac deactivation in NF-κB signalling using a minimal mathematical model.

Witt J, Konrath F, Sawodny O, Ederer M, Kulms D, Sauter T.

PLoS One. 2012;7(7):e40274. doi: 10.1371/journal.pone.0040274. Epub 2012 Jul 18.


Modeling time delay in the NFκB signaling pathway following low dose IL-1 stimulation.

Witt J, Barisic S, Sawodny O, Ederer M, Kulms D, Sauter T.

EURASIP J Bioinform Syst Biol. 2011 Jun 17;2011(1):3. doi: 10.1186/1687-4153-2011-3.


The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.

Niessner H, Beck D, Sinnberg T, Lasithiotakis K, Maczey E, Gogel J, Venturelli S, Berger A, Mauthe M, Toulany M, Flaherty K, Schaller M, Schadendorf D, Proikas-Cezanne T, Schittek B, Garbe C, Kulms D, Meier F.

J Invest Dermatol. 2011 Feb;131(2):468-79. doi: 10.1038/jid.2010.297. Epub 2010 Oct 14.


Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis.

Hörnle M, Peters N, Thayaparasingham B, Vörsmann H, Kashkar H, Kulms D.

Oncogene. 2011 Feb 3;30(5):575-87. doi: 10.1038/onc.2010.434. Epub 2010 Sep 20.


Tyrosine phosphatase inhibition triggers sustained canonical serine-dependent NFkappaB activation via Src-dependent blockade of PP2A.

Barisic S, Schmidt C, Walczak H, Kulms D.

Biochem Pharmacol. 2010 Aug 15;80(4):439-47. doi: 10.1016/j.bcp.2010.04.028. Epub 2010 May 5.


Mechanism of PP2A-mediated IKK beta dephosphorylation: a systems biological approach.

Witt J, Barisic S, Schumann E, Allgöwer F, Sawodny O, Sauter T, Kulms D.

BMC Syst Biol. 2009 Jul 16;3:71. doi: 10.1186/1752-0509-3-71.


Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.

Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D, Maczey E, Campos M, Gogel J, Garbe C, Meier F.

J Invest Dermatol. 2009 Jun;129(6):1500-15. doi: 10.1038/jid.2008.379. Epub 2008 Dec 11.


Sensitization of melanoma cells to TRAIL by UVB-induced and NF-kappaB-mediated downregulation of xIAP.

Thayaparasingham B, Kunz A, Peters N, Kulms D.

Oncogene. 2009 Jan 22;28(3):345-62. doi: 10.1038/onc.2008.397. Epub 2008 Nov 3.


Identification of PP2A as a crucial regulator of the NF-kappaB feedback loop: its inhibition by UVB turns NF-kappaB into a pro-apoptotic factor.

Barisic S, Strozyk E, Peters N, Walczak H, Kulms D.

Cell Death Differ. 2008 Nov;15(11):1681-90. doi: 10.1038/cdd.2008.98. Epub 2008 Jun 27.


Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.

Lasithiotakis KG, Sinnberg TW, Schittek B, Flaherty KT, Kulms D, Maczey E, Garbe C, Meier FE.

J Invest Dermatol. 2008 Aug;128(8):2013-23. doi: 10.1038/jid.2008.44. Epub 2008 Mar 6.


Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.

Meier F, Busch S, Lasithiotakis K, Kulms D, Garbe C, Maczey E, Herlyn M, Schittek B.

Br J Dermatol. 2007 Jun;156(6):1204-13. Epub 2007 Mar 28.


NF-kappaB and cytokines.

Kulms D, Schwarz T.

Vitam Horm. 2006;74:283-300. Review.


Differential effects of NF-kappaB on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome.

Strozyk E, Pöppelmann B, Schwarz T, Kulms D.

Oncogene. 2006 Oct 12;25(47):6239-51. Epub 2006 May 15.


NF{kappa}B-dependent down-regulation of tumor necrosis factor receptor-associated proteins contributes to interleukin-1-mediated enhancement of ultraviolet B-induced apoptosis.

Pöppelmann B, Klimmek K, Strozyk E, Voss R, Schwarz T, Kulms D.

J Biol Chem. 2005 Apr 22;280(16):15635-43. Epub 2005 Feb 21.


20 years after--milestones in molecular photobiology.

Kulms D, Schwarz T.

J Investig Dermatol Symp Proc. 2002 Dec;7(1):46-50. Review.


Molecular mechanisms involved in UV-induced apoptotic cell death.

Kulms D, Schwarz T.

Skin Pharmacol Appl Skin Physiol. 2002 Sep-Oct;15(5):342-7. Review.


Independent contribution of three different pathways to ultraviolet-B-induced apoptosis.

Kulms D, Schwarz T.

Biochem Pharmacol. 2002 Sep;64(5-6):837-41. Review.


Apoptosis induced by disruption of the actin cytoskeleton is mediated via activation of CD95 (Fas/APO-1).

Kulms D, Düssmann H, Pöppelmann B, Ständer S, Schwarz A, Schwarz T.

Cell Death Differ. 2002 Jun;9(6):598-608.


Mechanisms of UV-induced signal transduction.

Kulms D, Schwarz T.

J Dermatol. 2002 Apr;29(4):189-96. Review.


Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair.

Schwarz A, Ständer S, Berneburg M, Böhm M, Kulms D, van Steeg H, Grosse-Heitmeyer K, Krutmann J, Schwarz T.

Nat Cell Biol. 2002 Jan;4(1):26-31.


The molecular determinants of sunburn cell formation.

Murphy G, Young AR, Wulf HC, Kulms D, Schwarz T.

Exp Dermatol. 2001 Jun;10(3):155-60.


Molecular mechanisms of UV-induced apoptosis.

Kulms D, Schwarz T.

Photodermatol Photoimmunol Photomed. 2000 Oct;16(5):195-201. Review.


Nuclear and cell membrane effects contribute independently to the induction of apoptosis in human cells exposed to UVB radiation.

Kulms D, Pöppelmann B, Yarosh D, Luger TA, Krutmann J, Schwarz T.

Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7974-9.


Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand.

Kothny-Wilkes G, Kulms D, Pöppelmann B, Luger TA, Kubin M, Schwarz T.

J Biol Chem. 1998 Oct 30;273(44):29247-53.


Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L.

Aragane Y, Kulms D, Metze D, Wilkes G, Pöppelmann B, Luger TA, Schwarz T.

J Cell Biol. 1998 Jan 12;140(1):171-82.

Supplemental Content

Support Center